TYK MEDICINES-B(02410) will present the research results of five innovative drug projects at the 2026 AACR Annual Meeting.
Tongyuan Kang Pharmaceuticals-B (02410) has announced that the company will present the research progress and results of five innovative drug projects at the 2026 American Association for Cancer Research (AACR) annual meeting poster session. The projects include TY-0609 (CDK4 inhibitor), TY-2699a (CDK7 inhibitor), TY-2719 (EGFR/FAK (PROTAC) inhibitor), PI3K (PI3K inhibitor), and TY-1054 (YAP-TEAD inhibitor), all of which are independently developed anti-cancer small molecule innovative drug candidates by the company.
TYK Medicines-B (02410) announced that the company will present the research progress and results of five innovative drug projects at the 2026 American Association for Cancer Research (AACR) annual meeting poster session. The projects include TY-0609 (CDK4 inhibitor), TY-2699a (CDK7 inhibitor), TY-2719 (EGFR/FAK (PROTAC) inhibitor), PI3K (PI3K inhibitor), and TY-1054 (YAP-TEAD inhibitor), all of which are novel anti-tumor small molecule candidates developed by the company. The AACR annual meeting will be held in San Diego, USA from April 17th to April 22nd, 2026, and the company's poster presentations will take place from April 19th to April 21st.
Related Articles
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
